Matthew Griffin, described as “The Adviser behind the Advisers” and a “Young Kurzweil,” is the founder and CEO of the World Futures Forum and the 311 Institute, a global Futures and Deep Futures consultancy working between the dates of 2020 to 2070, and is an award winning futurist, and author of “Codex of the Future” series. Regularly featured in the global media, including AP, BBC, Bloomberg, CNBC, Discovery, RT, Viacom, and WIRED, Matthew’s ability to identify, track, and explain the impacts of hundreds of revolutionary emerging technologies on global culture, industry and society, is unparalleled. Recognised for the past six years as one of the world’s foremost futurists, innovation and strategy experts Matthew is an international speaker who helps governments, investors, multi-nationals and regulators around the world envision, build and lead an inclusive, sustainable future. A rare talent Matthew’s recent work includes mentoring Lunar XPrize teams, re-envisioning global education and training with the G20, and helping the world’s largest organisations envision and ideate the future of their products and services, industries, and countries. Matthew's clients include three Prime Ministers and several governments, including the G7, Accenture, Aon, Bain & Co, BCG, Credit Suisse, Dell EMC, Dentons, Deloitte, E&Y, GEMS, Huawei, JPMorgan Chase, KPMG, Lego, McKinsey, PWC, Qualcomm, SAP, Samsung, Sopra Steria, T-Mobile, and many more.
WHY THIS MATTERS IN BRIEF
What if you could train the human immune system to spot and kill cancerous cells by developing a vaccine? You’d change the outcome …
Love the Exponential Future? Join our XPotential Community, future proof yourself with courses from XPotential University, read about exponential tech and trends, connect, watch a keynote, or browse my blog.
An ounce of prevention is worth a pound of cure, so they say, and recently I’ve seen numerous cancer breakthroughs that have enough potential to give people hope that one day the deadly diseases’ days will be numbered. From cancer vaccines and animal shaped nanomachines, to deadly nanoparticles and nanobots that drill through cancer cells walls and stunningly effective personalised gene therapies, there are tons of promising future treatments in the works.
Now, in another development, scientists have shown off another new potential cancer vaccine that involves injections of dormant tumor cells to stimulate the body’s immune system and help prevent the onset of cancer in the first place.
The Future of Work and Healthcare, by keynote speaker Matthew Griffin
A cancer vaccine would be something of a Holy Grail to modern medicine, and unsurprisingly there are a lot of people focused on creating one – some successfully albeit with different results and caveats. Some techniques would be therapeutic, fighting cancer that’s already present in a patient, while others could be preventative, designed to reduce the risk of cancer forming in the first place. Either way, these vaccines would work by stimulating the immune system to recognize cancer.
The team from the Institute for Research in Biomedicine (IRB) in Spain had previously developed a pseudo-cancer vaccine that stimulated immune responses by administering dead tumor cells, but in the new study they had more success using cancer cells that were in a dormant state known as senescence.
As cells age and accumulate DNA damage, they eventually reach a point where they stop dividing, but instead of dying off they lie dormant. These so-called senescent or “zombie” cells are implicated in many of the symptoms of aging, but they appear to be a protective mechanism against cancer, which is essentially uncontrolled cell division.
So, for the new study, the IRB team investigated whether senescent tumor cells could be used instead of dead ones to stimulate an immune response. After all, they still have the same markers that immune cells are on the lookout for, but without the risk of them growing and dividing.
The researchers vaccinated healthy mice with senescent tumor cells, then one week later injected them with live melanoma or pancreatic cancer cells. And sure enough, the number of mice that went on to develop tumors was significantly reduced in the group that received senescent tumor cells, compared to controls inoculated with cancer cells in the process of dying.
The team also administered the senescent cell vaccines to mice that already had developed tumors, and found some improvements there too, albeit not to the same extent as the prophylactic treatment.
Closer examination revealed that the senescent cells were highly efficient in stimulating important immune cells – dendritic cells and CD8 T cells – against the cancer.
“Our study concludes that the induction of senescence in tumor cells improves the recognition of these cells by the immune system and it also increases the intensity of the response they generate,” said Inés Marín, first author of the study. “So our findings are very positive.”
Of course, results in animal models don’t always translate to humans, so there’s still plenty of work left to do. The team is currently testing how well the senescent cell vaccine might work in combination with immunotherapy treatments – a one-two punch that’s shown promise in other studies. The research was published in the journal Cancer Discovery.
Source: IRB Barcelona